SCHEMBL6779273

SCHEMBL6779273

CCOC(=O)c1cccc(NC(=O)NC[C@@H]2CC[C@H](Cc3ccccc3)CN2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
THRB P10828 1/20 0.51
NAMPT P43490 2/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
CCR3 P51677 1/20 0.50
SLC6A3 Q01959 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
PPIA P62937 1/20 0.47
RAB9A P51151 5/20 0.46
KMT2A Q03164 4/20 0.46
NPC1 O15118 3/20 0.46
MEN1 O00255 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.46
POLB P06746 2/20 0.45
PKM P14618 1/20 0.45
TSHR P16473 2/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771651 1.00 MAPT (0.51) MAPTTHRBNAMPTSLC6A2SLC6A4
SCHEMBL6772953 0.93 CCR3 (0.53) SLC6A2SLC6A4CCR3SLC6A3PPIA
SCHEMBL6773843 0.93 CCR3 (0.53) SLC6A2SLC6A4CCR3SLC6A3PPIA
SCHEMBL6779206 0.92 CCR3 (0.52) MAPTTHRBNAMPTSLC6A2SLC6A4
SCHEMBL6779061 0.92 CCR3 (0.52) MAPTTHRBNAMPTSLC6A2SLC6A4
SCHEMBL6769374 0.89 CCR3 (0.61) SLC6A2SLC6A4CCR3SLC6A3KMT2A
SCHEMBL6774880 0.89 CCR3 (0.61) SLC6A2SLC6A4CCR3SLC6A3KMT2A
SCHEMBL6769043 0.87 CCR3 (0.65) MAPTTHRBNAMPTSLC6A2SLC6A4
SCHEMBL6774529 0.87 CCR3 (0.65) MAPTTHRBNAMPTSLC6A2SLC6A4
SCHEMBL6773638 0.85 CCR3 (0.55) SLC6A2SLC6A4CCR3SLC6A3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6706735-B2 NITROGEN COMPOUNDS SUCH AS N-(3-(4-BENZYL-2-PIPERIDINYL)PROPYL )-N'-(3-CYANOPHENYL)UREA, USED AS CHEMOTACTIC CYTOKINE CONTROLLERS ADMINISTERED FOR PROPHYLAXIS OF ASTHMA, ALLERGIES AND AUTOIMMUNE DISEASES BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-16 US disclosed
US-20030144273-A1 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity WATSON PAUL S (US) 2003-07-31 US disclosed
US-6441001-B1 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144273-A1 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity CCR3, CCR1, CCR4 MAPT 4786/4885THRB 2182/4885NAMPT 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.